Morocco Health Ministry cuts cancer drug prices by up to 40%
Morocco's Ministry of Health and Social Protection has cut prices on hundreds of brand-name and generic medicines, including cancer and chronic disease drugs.
Morocco's Ministry of Health and Social Protection is cutting the prices of hundreds of brand-name and generic medicines sold in the country, starting with drugs for chronic diseases, cardiovascular conditions and cancer, under a new decision published in the latest issue of the Official Gazette. Decision No. 2157.26, dated September 22, 2026, amends and supplements Decision No. 787.14 of April 7, 2014, which sets the public sale prices of brand-name, generic and biosimilar medicines marketed in Morocco.
Price cuts worth thousands of dirhams for some treatments
The lists attached to the decision show a sweeping review of prices for hundreds of medicines, with significant cuts reaching thousands of dirhams for some specialized treatments, particularly cancer and serious-illness drugs. Here are examples of medicines covered by the cuts, according to the published lists:
| Medicine | Previous price | New price |
|---|---|---|
| CRESTOR 10 mg (box of 30 tablets) | 167.00 MAD | 99.50 MAD |
| NO LIP 10 mg (box of 30 tablets) | 154.10 MAD | 99.50 MAD |
| IBRANCE 100 mg (box of 21 capsules) – targeted cancer therapy | 24,024.00 MAD | 17,066.00 MAD |
| ENBREL 50 mg (pre-filled injections) | 6,315.00 MAD | 5,005.00 MAD |
| ALECENSA 150 mg (box of 224 capsules) – cancer treatment | 44,479.00 MAD | 32,863.00 MAD |
| ELIQUIS 2.5 mg – cardiac anticoagulant | 188.50 MAD | 156.50 MAD |
| REFACTO AF 2000 IU – for hemophilia patients | 12,355.00 MAD | 7,509.00 MAD |
Why this decision now?
The decision is based on the Medicine and Pharmacy Code (Law No. 17-04) and the law establishing the Moroccan Agency for Medicines and Health Products (Law No. 10-22). It was developed in coordination with the inter-ministerial committee in charge of medicine pricing, on a proposal from the Agency. According to the Ministry of Health and Social Protection, the cuts are meant to improve citizens' purchasing power, preserve the balance of social protection funds and the Compulsory Health Insurance scheme (AMO) by reducing the treatment costs borne by insuring bodies, encourage the use of generic medicines, and ensure a steady national supply of medicines.
The decision comes as large segments of Moroccans, particularly low-income families, still forgo treatment because of its high cost, making the price cuts on drugs for serious illnesses such as cancer and heart disease a measure that directly affects the wallets of thousands of patients.